Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Where Are They Now? Checking In On Four Cardiovascular Start-Ups

This article was originally published in Start Up

Executive Summary

It's no secret increasing generic competition and regulatory oversight, combined with the financial challenges of developing a primary care drug, make cardiovascular a tough place for venture-backed biotechs. START-UP takes the pulse of four previously profiled cardiovascular companies -- arca Biopharma, Celladon, NovaCardia and Portola Pharmaceuticals, -- to see what lessons they've learned.

Related Content

Protein Rescues Function After Heart Failure
Despite Recent Setbacks, Merck's CV Pipeline Is Strong
Amarin Version 3.0 Weighs Its Options on Promising Omega-3 Pipeline
Biogen Idec Taps Exelixis' Scangos To Be New CEO
Pfizer Restructures for a More Flexible Future
Pfizer Restructures for a More Flexible Future
NovaCardia & Domain: New-Model Spec Pharma Investing
NovaCardia Inc.
Celladon Corp.
Portola: A Cardiovascular Boutique with Big Plans


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts